Learn more about INDiGO and Evotec's integrated preclinical development capabilities to de-risk and accelerate IND-enabling programs:
- Typically, drug candidates can be advanced from candidate selection to IND-submission in 48–52 weeks
- Our experienced team not only executes R&D projects, but also proactively contributes to your scientific strategy
- Clients can either opt for the full INDiGO platform or selected preclinical development and CMC components